Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Immunotherapy
Antibody-based drugs may be more effective when combined with IL-2 or IL-12
January 26th, 2006
A new study suggests that antibody-based cancer drugs might help patients more if they are given with substances that stimulate the immune system. The study is the first to indicate that the drug trastuzumab, also known as Herceptin, may work better when it is followed by injections of interleukin (IL) 2 or IL-12. Both substances trigger the activity of immune cells known as natural killer (NK) cells. The research, by scientists at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, was published in the January 1, 2006, issue of the journal Cancer Research. ...
Source: Women's Health Weekly (2006-01-26)
|
